SUPLEXA

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

About Alloplex Biotherapeutics

Founded in 2016, Alloplex Biotherapeutics is developing a patented immune cell retraining platform (ENLIST) that activates multiple immune pathways simultaneously to create potent, non-genetically engineered therapeutic cells. Its lead program, SUPLEXA, achieved all endpoints in a Phase 1 trial in 35 heavily pre-treated solid tumor patients, showing a pristine safety profile and clinical activity, including complete and partial responses. The company is positioned at the forefront of next-generation cellular therapy, with a scalable manufacturing process and a platform capable of augmenting CAR-T and allogeneic approaches.

Therapeutic Areas